Exelixis EXEL Business Segments — Development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept exel:DevelopmentExpenses.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's business segments — development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's business segments — development?
- Exelixis (EXEL) reported business segments — development of $135.72M in Q1 2026.
- How has Exelixis's business segments — development changed year-over-year?
- Exelixis's business segments — development decreased by 11.4% year-over-year, from $153.22M to $135.72M.
- What is the long-term trend for Exelixis's business segments — development?
- Over 3 years (2022 to 2025), Exelixis's business segments — development has grown at a 2.9% compound annual growth rate (CAGR), from $521.62M to $567.84M.
- What does business segments — development mean?
- Spending on clinical trials and the regulatory process to bring drugs to market.
- How do you interpret business segments — development?
- High development costs are necessary for future growth but represent significant capital risk if clinical trials fail.
- How does business segments — development compare across companies?
- Comparable to 'Clinical Development' or 'Late-stage R&D' expenses at peer pharmaceutical companies.